In the world of biotech, communicating groundbreaking research has always been key to moving science forward. But let’s face it—while peer-reviewed journals and academic conferences are crucial, they tend to speak to a niche audience. The real magic happens when these discoveries break into the mainstream media. When The New York Times or The Wall Street Journal runs a story, the public takes notice, and that attention can spark serious momentum. Whether it’s about recruiting clinical trial participants, attracting investment, or simply educating people about emerging health challenges, the media’s spotlight has helped propel biotech into the future of healthcare.
Starting out when biotech was… new?
I founded Russo Partners in 1988, back when the term “biotech” was hardly even defined. To give you an idea, there were only about 20 biotech companies back then. The idea of starting a healthcare-focused communications firm in this tiny, unproven field didn’t exactly scream “sure thing.” But here we are, more than three decades later, and biotech is now one of the most influential industries on the planet. It wasn’t just the science that evolved—it was the storytelling. Back then, no one was paying attention to the kinds of technologies we were working with, at least not outside the scientific community. But as we began helping companies share their stories, things started to shift. Major outlets picked up on the potential of biotech, and before long, the industry had its first moment in the spotlight.
The biotech boom: From the Human Genome to Dolly the sheep
The Human Genome Project (HGP) was one of the biggest tipping points in biotech. It was a massive, unprecedented effort to map our entire genetic code, and the excitement around it was palpable. When The New York Times ran a front-page story in 1993, the world began to grasp the enormity of what was happening. But the real media frenzy came in 1998, when Celera Genomics (now Celera Corporation) announced it would complete the genome sequence in just three years, setting off a race with the U.S. government. The culmination came in 2000, when Bill Clinton and Tony Blair announced the completion of the genome sequencing—a defining moment that signaled biotech’s arrival on the global stage.
At the same time, Dolly the sheep was making headlines around the world. Cloned from a single cell in 1996, Dolly represented a huge leap forward in reproductive biotechnology. It wasn’t just a scientific achievement—it was a moment that sparked the imagination of people everywhere. The cloning of Dolly led to conversations about the future of medicine, ethics, and the limits of what science could achieve. The world realized that biotechnology had the potential to change everything.
Biotech meets AI: The next frontier
Now, as we stand at the crossroads of biotechnology and artificial intelligence, the potential for life-changing innovation is greater than ever. AI is helping researchers analyze vast amounts of clinical and genomic data, identifying potential treatments more efficiently than ever before. It’s speeding up drug discovery and moving us closer to the holy grail of precision medicine—tailoring treatments to an individual’s genetic makeup. And just like before, media coverage is crucial. When the public understands the impact of these innovations, it creates a ripple effect that can accelerate their development.
Another exciting area is bioelectronics—the merging of biology and electronics to treat conditions like Parkinson’s, epilepsy, and heart arrhythmias. Imagine a future where diseases are treated not just with drugs, but with targeted electronic signals. These breakthroughs will continue to make headlines as they reshape healthcare, just like the milestones we’ve seen in the past.
Why media matters in biotech’s future
If there’s one thing I’ve learned from more than 30 years of working in biotech communications, it’s this: science alone doesn’t drive progress. People need to know about these breakthroughs. And the way they learn about them matters. When we take these innovations out of the lab and into the public consciousness—through front-page stories, TV segments, and online coverage—the impact is undeniable. We see more funding for research, more clinical trials, and more widespread understanding of diseases that were once only known in niche circles. That’s how biotech changes lives.
As we look to the future, I believe the media will continue to play a critical role in shaping the trajectory of biotechnology. Every new advancement is an opportunity to tell a story—one that can spark interest, build momentum, and ultimately improve healthcare for millions of people. We’ve come a long way, but the biotech story is far from over. And I, for one, am excited to see where it goes next.
About the Author
Tony Russo, Ph.D., is Chairman and CEO of Russo Partners, a strategic communications firm serving biopharma, medtech, and digital health leaders for more than 35 years.
